| WO2013086373 |
Alnylam Pharmaceuticals,
USA |
Lipids for the delivery of nucleic acids |
LNP components for RNA delivery |
| WO2014093924 |
Moderna, USA |
Preparation, cytotoxicity, apoptosis, and transcription of
modified nucleic acid molecules and uses thereof |
Modification
of mRNA |
| WO2016070166 |
Arcturus Therapeutics, USA |
Translatable
messenger RNA analogs containing unlocked nucleomonomers
and with prolonged in vivo half-lives for therapeutic uses |
mUNA or mRNA analogs with unlocked nucleomonomers |
| US10808242 |
BioNTech, Germany |
Method for reducing immunogenicity
of RNA by constructing A-rich
and U-poor mRNA for use in therapy |
mRNA modifications
for decreasing nonspecific immunogenicity
by mRNA itself |
| WO2017117528 |
Acuitas Therapeutics, Canada |
Preparation
of lipids and lipid nanoparticle formulations for
delivery of nucleic acids |
LNP components and formulation
for nucleic acid delivery |
| WO2017176974 |
The Ohio State University,
USA |
Biodegradable amino-ester nanomaterials for nucleic
acid delivery |
LNPs for delivery of RNAs including siRNA,
miRNA, and mRNA |
| WO2017212009 |
Curevac AG, Germany |
Hybrid carriers
comprising cationic peptide or polymer and
lipidoid |
A nucleic acid delivery system comprised of
a cationic peptide
or polymer and a lipidoid compound |
| US20180125989 |
Translate Bio, USA |
Imidazole cholesterol ester (ICE)-based lipid nanoparticle
formulation for delivery of mRNA |
Methods of formulating
nucleic acid containing LNP |
| WO2018009838 |
Rubius Therapeutics, USA |
Compositions and methods related to therapeutic erythroid cell
systems expressing exogenous RNA encoding a protein |
Therapeutic erythroid cell systems expressing exogenous RNA
encoding a protein |
| WO2018013525 |
Translate Bio, USA |
Nucleic acid conjugates
and uses thereof |
Conjugates comprising sugars, folates
and cell-penetrating
peptides for delivering mRNA |
| WO2019092145 |
Evox Therapeutics, U.K. |
Exosomes comprising RNA therapeutics |
Methods
for using extracellular vesicles to encapsulating nucleic
acid-based therapeutics such as mRNA, circular RNA, miRNA, etc. |
| WO2020070040 |
Johannes Gutenberg-University Mainz and BioNTech, Germany |
RNA particles comprising polysarcosine |
LNPs for
delivering mRNAs |
| WO2020061367 |
Moderna, USA |
Preparation of compounds
and lipid nanoparticle compositions
for intracellular delivery of therapeutic agents |
LNPs
for drug delivery |
| WO2020097540 |
Arbutus Biopharma Corp., Canada |
Methods
and lipid nanoparticles for delivering mRNA and siRNA
in treatment of diseases |
LNPs for mRNA delivery |
| WO2020263883 |
Moderna, USA |
Endonuclease-resistant messenger
RNA and uses thereof |
Chemically modified mRNA that increases
mRNA stability |
| CN110747214 |
Shenzhen Zhenzhi Medical Technology, China |
Preparation of mRNA-antibody fusion molecule and its use for
drug delivery |
Preparation of antibody–mRNA fusion/conjugate
with puromycin
as the linker for targeted delivery of mRNA therapeutics. |
| WO2020160397 |
Moderna, USA |
Methods of preparing lipid nanoparticles |
LNP formulation |
| WO2021001417 |
BioNTech, Germany |
RNA formulations suitable
for therapy |
Self-amplifying RNA formulated in various
polymers |
| WO2021231854 |
Moderna, USA |
Lipid nanoparticle compositions
comprising an mRNA therapeutic
and an effector molecule |
System that features a tethered
molecule to further increase
the level and/or activity of mRNA therapeutics formulated in LNP |
| WO2021257262 |
Yale University, USA |
Poly(amine-co-ester) polymers
with modified end groups and
enhanced pulmonary delivery |
PEGlyated poly(amine-co-ester)
polymers with modified end groups
for enhanced delivery of mRNA to the lung by inhalation |
| WO2022032154 |
Moderna, USA |
Compositions for the delivery of payload
molecules to airway |
LNPs comprising payload molecules
such as mRNA therapeutics
to be delivered to airway cells |
| WO2016176330 |
University of Pennsylvania,
USA; Acuitas Therapeutics, Canada |
Nucleoside-modified
mRNAs encoding antigens for inducing an
adaptive |
Modified antigen mRNA delivered in LNP induced
adaptive immune
response without inducing innate immunity |
| WO2020191103 |
Arcturus
Therapeutics, USA |
Method of making lipid-encapsulated
RNA nanoparticles |
Detailed method for making RNA-encapsulating
LNP |
| WO2021250263 |
eTheRNA Immunotherapie, Belgium |
Lipid
nanoparticles comprising ionizable lipid, phospholipid,
sterol, PEG lipid and mRNA |
LNP components for RNA delivery |
| WO2022175815 |
Pfizer, USA |
Methods of protecting RNA |
Methods of protecting RNA against degradation and components
comprising free amino acids for this purpose |
| WO2019246203 |
University
of Texas, USA |
Lipid nanoparticle compositions for delivery
of mRNA and long
nucleic acids |
Compositions for delivery of long nucleic
acids (>80 nucleotides),
such as mRNAs, including cationic ionizable lipid, phospholipid, PEGylated
lipid, and a steroid |
| WO2022236093 |
Carnegie Mellon University, USA |
Lipid
nanoparticle-mediated mRNA delivery to the pancreas |
LNP composition for mRNA delivery to the pancreas containing:
cationic helper lipid, cholesterol analog, PEG-based compound, ionizable
lipidoid, and mRNA |
| US20230043677 |
Oregon State University, USA |
Inhalable
therapeutics |
Nanoparticles for mRNA delivery suitable
for nebulization and/or
delivering mRNA by inhalation |
| WO2022155598 |
Tufts College and Brigham
and Women’s Hospital, USA |
Lipid nanoparticles
for targeted delivery of mRNA |
LNP composition for specific
delivery of CRISPR-Cas9 mRNA to
the lung or liver |
